Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
TRACON Pharmaceuticals Inc (NASDAQ: TCON) closed the day trading at $2.29 up 33.92% from the previous closing price of $1.71. In other words, the price has increased by $33.92 from its previous closing price. On the day, 1.99 million shares were traded. TCON stock price reached its highest trading level at $2.89 during the session, while it also had its lowest trading level at $1.71.
Ratios:
For a better understanding of TCON, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.42. For the most recent quarter (mrq), Quick Ratio is recorded 0.89 and its Current Ratio is at 0.89.
On February 10, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $24.
H.C. Wainwright reiterated its Buy rating for the stock on December 23, 2019, while the target price for the stock was revised from $15 to $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 27 ’23 when THEUER CHARLES bought 47,000 shares for $0.75 per share. The transaction valued at 35,250 led to the insider holds 399,417 shares of the business.
THEUER CHARLES bought 3,999 shares of TCON for $2,639 on Apr 26 ’23. The President and CEO now owns 352,417 shares after completing the transaction at $0.66 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCON now has a Market Capitalization of 5210253 and an Enterprise Value of -2385734. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43. Its current Enterprise Value per Revenue stands at -0.198 whereas that against EBITDA is 0.347.
Stock Price History:
The Beta on a monthly basis for TCON is 1.26, which has changed by -0.9356742 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, TCON has reached a high of $41.00, while it has fallen to a 52-week low of $1.59. The 50-Day Moving Average of the stock is -55.85%, while the 200-Day Moving Average is calculated to be -49.48%.
Shares Statistics:
Over the past 3-months, TCON traded about 193.75K shares per day on average, while over the past 10 days, TCON traded about 444676 shares per day. A total of 2.21M shares are outstanding, with a floating share count of 2.10M. Insiders hold about 7.89% of the company’s shares, while institutions hold 11.02% stake in the company. Shares short for TCON as of 1711584000 were 37245 with a Short Ratio of 0.49, compared to 1709164800 on 22433. Therefore, it implies a Short% of Shares Outstanding of 37245 and a Short% of Float of 1.6500000000000001.
Earnings Estimates
At present, 2 analysts are actively evaluating the performance of TRACON Pharmaceuticals Inc (TCON) in the stock market.On average, analysts expect EPS of -$1.19 for the current quarter, with a high estimate of -$1.18 and a low estimate of -$1.2, while EPS last year was -$7.2. The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.99 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$4.04 and -$5.2 for the fiscal current year, implying an average EPS of -$4.62. EPS for the following year is -$3.43, with 2 analysts recommending between -$1.2 and -$5.66.
